Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19003368rdf:typepubmed:Citationlld:pubmed
pubmed-article:19003368lifeskim:mentionsumls-concept:C0012984lld:lifeskim
pubmed-article:19003368lifeskim:mentionsumls-concept:C0596995lld:lifeskim
pubmed-article:19003368lifeskim:mentionsumls-concept:C1517499lld:lifeskim
pubmed-article:19003368pubmed:issue1-3lld:pubmed
pubmed-article:19003368pubmed:dateCreated2008-11-12lld:pubmed
pubmed-article:19003368pubmed:abstractTextWe have developed and characterized cultures of healthy and dystrophic canine myoblasts for the evaluation of various gene transfer protocols. The number of desmin-positive myoblasts was elevated (>>80%) in cultures of myoblasts obtained from different muscle territories, the diaphragm muscle giving rise to the purest cultures. Myoblasts from dogs turned out to be a very convenient source of well transfectable and transducible cells. Transfection with plasmid DNA allowed efficient transgene expression (50% of beta-galactosidase positive cells and about 375 ng luciferase/mg protein after transfection with a calcium phosphate-precipitated plasmid). Infection with high concentrations of adenoviral and retroviral vectors allowed transgene (beta-galactosidase or mini-dystrophin) detection in about 75 to 90% of the canine cells. Therefore, primary dog myoblast cultures represent a useful in vitro model for viral and non-viral gene delivery, as well as for functional evaluation and cell grafting with applications in genetic diseases, vaccination or production of circulating therapeutic proteins.lld:pubmed
pubmed-article:19003368pubmed:languageenglld:pubmed
pubmed-article:19003368pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19003368pubmed:statusPubMed-not-MEDLINElld:pubmed
pubmed-article:19003368pubmed:monthJullld:pubmed
pubmed-article:19003368pubmed:issn0920-9069lld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:BraunSSlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:BischoffRRlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:LuskyMMlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:PaviraniAAlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:PerraudFFlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:ClaudepierreM...lld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:MehtaliMMlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:ThioudelletCClld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:HomannHHlld:pubmed
pubmed-article:19003368pubmed:authorpubmed-author:EscriouCClld:pubmed
pubmed-article:19003368pubmed:issnTypePrintlld:pubmed
pubmed-article:19003368pubmed:volume30lld:pubmed
pubmed-article:19003368pubmed:ownerNLMlld:pubmed
pubmed-article:19003368pubmed:authorsCompleteYlld:pubmed
pubmed-article:19003368pubmed:pagination181-9lld:pubmed
pubmed-article:19003368pubmed:year1999lld:pubmed
pubmed-article:19003368pubmed:articleTitleGene transfer into canine myoblasts.lld:pubmed
pubmed-article:19003368pubmed:affiliationTRANSGENE S.A., 11 rue de Molsheim, 67082, Strasbourg Cedex, France.lld:pubmed
pubmed-article:19003368pubmed:publicationTypeJournal Articlelld:pubmed